| Literature DB >> 33597532 |
Micah T McClain1,2,3, Florica J Constantine4, Ricardo Henao4, Yiling Liu4, Ephraim L Tsalik5,4,6, Thomas W Burke4, Julie M Steinbrink4,6, Elizabeth Petzold4, Bradly P Nicholson7, Robert Rolfe6, Bryan D Kraft5,4,8, Matthew S Kelly8, Daniel R Saban9, Chen Yu9, Xiling Shen10, Emily M Ko4, Gregory D Sempowski11, Thomas N Denny11, Geoffrey S Ginsburg4, Christopher W Woods5,4,6.
Abstract
SARS-CoV-2 infection has been shown to trigger a wide spectrum of immune responses and clinical manifestations in human hosts. Here, we sought to elucidate novel aspects of the host response to SARS-CoV-2 infection through RNA sequencing of peripheral blood samples from 46 subjects with COVID-19 and directly comparing them to subjects with seasonal coronavirus, influenza, bacterial pneumonia, and healthy controls. Early SARS-CoV-2 infection triggers a powerful transcriptomic response in peripheral blood with conserved components that are heavily interferon-driven but also marked by indicators of early B-cell activation and antibody production. Interferon responses during SARS-CoV-2 infection demonstrate unique patterns of dysregulated expression compared to other infectious and healthy states. Heterogeneous activation of coagulation and fibrinolytic pathways are present in early COVID-19, as are IL1 and JAK/STAT signaling pathways, which persist into late disease. Classifiers based on differentially expressed genes accurately distinguished SARS-CoV-2 infection from other acute illnesses (auROC 0.95 [95% CI 0.92-0.98]). The transcriptome in peripheral blood reveals both diverse and conserved components of the immune response in COVID-19 and provides for potential biomarker-based approaches to diagnosis.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33597532 PMCID: PMC7889643 DOI: 10.1038/s41467-021-21289-y
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919